776-777 / 1578
SBRT vs no treatment (NCDB)
Nanda RH, Cancer 2015
3147 pathology-proven patients >70 years (2003-2006)
No treatment = 2889 patients (92%)
;
SBRT = 258 patients (8%)
No significant differences in Charlson/Deyo comorbidity index
scores
US National Cancer Database
(NCDB)
Median survival (MS) with only
observation was
10.1 months
MS with SABR was
29 months